Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cti Biopharm Corp (CTIC)

Cti Biopharm Corp (CTIC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 662,519
  • Shares Outstanding, K 108,967
  • Annual Sales, $ 0 K
  • Annual Income, $ -97,910 K
  • 60-Month Beta 0.87
  • Price/Sales 254.28
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CTIC with:

Options Overview Details

View History
  • Implied Volatility 111.50% ( -0.27%)
  • Historical Volatility 95.22%
  • IV Percentile 41%
  • IV Rank 28.24%
  • IV High 266.68% on 11/17/21
  • IV Low 50.42% on 07/21/21
  • Put/Call Vol Ratio 0.20
  • Today's Volume 397
  • Volume Avg (30-Day) 1,985
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 29,041
  • Open Int (30-Day) 47,382

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.23
  • Prior Year -0.21
  • Growth Rate Est. (year over year) -4.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.95 +22.83%
on 06/13/22
6.52 -6.75%
on 06/09/22
+0.14 (+2.36%)
since 06/01/22
3-Month
3.32 +83.13%
on 05/11/22
6.52 -6.75%
on 06/09/22
+1.73 (+39.77%)
since 04/01/22
52-Week
1.43 +325.17%
on 12/02/21
6.52 -6.75%
on 06/09/22
+3.50 (+135.66%)
since 07/01/21

Most Recent Stories

More News
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors...

CTIC : 6.08 (+1.84%)
Why CTI Biopharma Stock Is Surging Today

A strong launch for the company's first commercialized drug drew a cheer from investors.

CTIC : 6.08 (+1.84%)
INCY : 77.67 (+2.24%)
CTI BioPharma (CTIC) Reports Q1 Loss, Tops Revenue Estimates

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5.71% and 6.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CTIC : 6.08 (+1.84%)
QTNT : 0.2400 (unch)
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating

Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer...

BIOV.CN : 0.100 (-4.76%)
BVAXF : 0.0850 (+6.25%)
CTIC : 6.08 (+1.84%)
IMGN : 4.61 (+2.44%)
CLVS : 2.85 (+58.33%)
SBFM : 1.1400 (+5.56%)
CTI BioPharma (CTIC) Reports Q4 Loss, Lags Revenue Estimates

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -35.71% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

CTIC : 6.08 (+1.84%)
USNA : 75.00 (+3.65%)
Should You Buy CTI BioPharma (CTIC) After Golden Cross?

Is it a good or bad thing when a stock experiences a golden cross technical event?

CTIC : 6.08 (+1.84%)
Ongoing R&D Leading to Discovery of More Efficient Therapies for Acute Myeloid Leukemia Therapeutics

Palm Beach, FL – December 15, 2021 – FinancialNewsMedia.com News Commentary – Acute Myeloid Leukemia (AML) is a type of blood cancer which usually affects white blood cells (WBCs), however, it can...

ONCY : 0.9900 (-1.98%)
ONC.TO : 1.26 (-3.82%)
GRTX : 1.2900 (-0.77%)
VLON : 0.6200 (-3.08%)
ALZN : 0.8754 (+1.27%)
CTIC : 6.08 (+1.84%)
2 Biotech Stocks Under $10 Wall Street Predicts Will Triple in Price

An increasing focus on integrating advanced technologies into research efforts to generate viable drugs for treating various critical ailments, and growing demand for therapies from an aging population,...

ESPR : 6.45 (+1.42%)
CTIC : 6.08 (+1.84%)
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma

The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma

CTIC : 6.08 (+1.84%)
AMGN : 245.55 (+0.92%)
VRTX : 287.32 (+1.96%)
BPMC : 49.93 (-1.15%)
DCPH : 13.26 (+0.84%)
Biotech Stock Roundup: VRTX, AMGN's Pipeline Updates, BPMC's Acquisition & More

Pipeline updates from Vertex (VRTX) and Amgen (AMGN) and other acquisition and regulatory updates have been the biotech sector's few key highlights during the past week.

CTIC : 6.08 (+1.84%)
AMGN : 245.55 (+0.92%)
VRTX : 287.32 (+1.96%)
BPMC : 49.93 (-1.15%)
DCPH : 13.26 (+0.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its...

See More

Key Turning Points

3rd Resistance Point 6.64
2nd Resistance Point 6.37
1st Resistance Point 6.22
Last Price 6.08
1st Support Level 5.81
2nd Support Level 5.54
3rd Support Level 5.39

See More

52-Week High 6.52
Last Price 6.08
Fibonacci 61.8% 4.58
Fibonacci 50% 3.97
Fibonacci 38.2% 3.37
52-Week Low 1.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar